Thetis Pharmaceuticals Announces Patent Issuance in Korea for First-in-Class Resolvin E1 Drug

Patent expands coverage to the 3rd largest market in Asia

Essex, CT – (August 24, 2022) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a small molecule ChemR23 agonist to treat cancer and chronic inflammatory diseases, announced that the Korea Intellectual Property Office has granted patent KR 10-2437682 providing composition of matter protection for TP-317.

 “TP-317 is a novel small molecule that represents a highly differentiated approach to regulating immune homeostasis with broad therapeutic potential in cancer and chronic inflammatory diseases,” said Gary Mathias, co-founder and CEO of Thetis. “With long-term patents issued in the U.S., Europe, Japan, China and now Korea, TP-317 has the intellectual property foundation to support clinical development throughout Asia.”

About Thetis Pharmaceuticals
Overview: TP-317 is a patented small molecule drug that delivers Resolvin E1, an endogenous lipid mediator that engages BLT1 as a biased agonist to promote immune homeostasis . Unlike anti-inflammatory drugs and anti-cancer agents that are immuno-suppressive, TP-317 activates innate and adaptive immune pathways to treat disease without compromising host-protective immunity.

IBD Program: TP-317 is being developed in IBD as first-line, oral therapy for moderate-to-severe Crohn’s disease and as second-line, oral therapy for moderate-to-severe ulcerative colitis in patients who are not well controlled on existing therapies. The anticipated high safety premium and unique epithelial repair mechanism of TP-317 supports its use as adjunct therapy to standard-of-care biologics and oral immunomodulators.

Cancer Program: TP-317 is being developed in cancer as an adjunct to standard of care therapy in advanced colorectal cancer and advanced non-small-cell lung cancer (NSCLC). Its unique myeloid-directed antigen presentation mechanism of action addresses a fundamental need in immunotherapy. Preclinical studies with oral TP-317 in tumor models of these cancers have shown potent single-agent activity, and enhanced efficacy when combined with immune checkpoint inhibitors, chemotherapy and their combination.

Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration. 

Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com